{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,9]],"date-time":"2026-03-09T18:23:02Z","timestamp":1773080582654,"version":"3.50.1"},"reference-count":7,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,11,16]]},"DOI":"10.7759\/cureus.97020","type":"journal-article","created":{"date-parts":[[2025,11,17]],"date-time":"2025-11-17T07:30:50Z","timestamp":1763364650000},"source":"Crossref","is-referenced-by-count":1,"title":["Azacitidine Beyond the Bone Marrow: An Unexpected Journey Into Azacitidine-Induced Arthropathy"],"prefix":"10.7759","author":[{"given":"Syamasis","family":"Bandyopadhyay","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arghya","family":"Sahu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sandip","family":"Kumar Chandra","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aheli","family":"Ghosh Dastidar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sourav","family":"Pratihar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1177\/10781552231180470","article-title":"Azacitidine as a rare cause of reactive arthritis in a patient with acute myeloid leukemia","volume":"29","author":"Alsaadi D","year":"2023","unstructured":"Alsaadi D, Low L, Zubairu M, Clesham K, Rowan F. Azacitidine as a rare cause of reactive arthritis in a patient with acute myeloid leukemia. J Oncol Pharm Pract. 2023, 29:1533-6. 10.1177\/10781552231180470","journal-title":"J Oncol Pharm Pract"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1177\/2040620712464882","article-title":"Azacitidine in the management of patients with myelodysplastic syndromes","volume":"3","author":"Khan C","year":"2012","unstructured":"Khan C, Pathe N, Fazal S, Lister J, Rossetti JM. Azacitidine in the management of patients with myelodysplastic syndromes. Ther Adv Hematol. 2012, 3:355-73. 10.1177\/2040620712464882","journal-title":"Ther Adv Hematol"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2004444","article-title":"Oral azacitidine maintenance therapy for acute myeloid leukemia in first remission","volume":"383","author":"Wei AH","year":"2020","unstructured":"Wei AH, D\u00f6hner H, Pocock C, et al.. Oral azacitidine maintenance therapy for acute myeloid leukemia in first remission\r\n. N Engl J Med. 2020, 383:2526-37. 10.1056\/NEJMoa2004444","journal-title":"N Engl J Med"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2012.144","article-title":"The novel cyclin-dependent kinase inhibitor dinaciclib (SCH727965) promotes apoptosis and abrogates microenvironmental cytokine protection in chronic lymphocytic leukemia cells","volume":"26","author":"Johnson AJ","year":"2012","unstructured":"Johnson AJ, Yeh YY, Smith LL, et al.. The novel cyclin-dependent kinase inhibitor dinaciclib (SCH727965) promotes apoptosis and abrogates microenvironmental cytokine protection in chronic lymphocytic leukemia cells. Leukemia. 2012, 26:2554-7. 10.1038\/leu.2012.144","journal-title":"Leukemia"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2020002351","article-title":"Modulation of IL-6\/STAT3 signaling axis in CD4+FOXP3- T cells represents a potential antitumor mechanism of azacitidine","volume":"5","author":"Lamprianidou E","year":"2021","unstructured":"Lamprianidou E, Kordella C, Kazachenka A, et al.. Modulation of IL-6\/STAT3 signaling axis in CD4+FOXP3- T cells represents a potential antitumor mechanism of azacitidine. Blood Adv. 2021, 5:129-42. 10.1182\/bloodadvances.2020002351","journal-title":"Blood Adv"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1177\/10781552211049728","article-title":"Recurrent arthritis as an unexpected side effect associated with azacitidine in a patient with myelodysplastic syndrome","volume":"28","author":"Iltar U","year":"2022","unstructured":"Iltar U, Alhan FN, Vural E, et al.. Recurrent arthritis as an unexpected side effect associated with azacitidine in a patient with myelodysplastic syndrome. J Oncol Pharm Pract. 2022, 28:500-3. 10.1177\/10781552211049728","journal-title":"J Oncol Pharm Pract"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.1982.tb01361.x","article-title":"Comparison of two recently published algorithms for assessing the probability of adverse drug reactions","volume":"13","author":"Busto U","year":"1982","unstructured":"Busto U, Naranjo CA, Sellers EM. Comparison of two recently published algorithms for assessing the probability of adverse drug reactions. Br J Clin Pharmacol. 1982, 13:223-7. 10.1111\/j.1365-2125.1982.tb01361.x","journal-title":"Br J Clin Pharmacol"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/421316-azacitidine-beyond-the-bone-marrow-an-unexpected-journey-into-azacitidine-induced-arthropathy","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,17]],"date-time":"2025-11-17T07:30:51Z","timestamp":1763364651000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/421316-azacitidine-beyond-the-bone-marrow-an-unexpected-journey-into-azacitidine-induced-arthropathy"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,16]]},"references-count":7,"URL":"https:\/\/doi.org\/10.7759\/cureus.97020","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2025,11,16]]}}}